Cargando…

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis

Purpose: To identify the optimal initial 5 years of adjuvant endocrine therapy for hormone receptor-positive postmenopausal early breast cancer (EBC) patients. Methods: We conducted a systematic search of the PubMed, Web of Science, and EMBASE to obtain relevant studies published between January 200...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Hao, Pei, Wendi, Zhong, Jianxin, Shao, Bin, Liu, Xiaoran, Liu, Yaxin, Zhang, Jiayang, Rugo, Hope S., Li, Huiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198062/ https://www.ncbi.nlm.nih.gov/pubmed/35721183 http://dx.doi.org/10.3389/fphar.2022.886954

Ejemplares similares

Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients
por: Jiang, Yantao, et al.
Publicado: (2023)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2021)

Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol
por: Liao, Hao, et al.
Publicado: (2022)

Natural Polysaccharides and Their Derivates: A Promising Natural Adjuvant for Tumor Immunotherapy
por: Li, Ye, et al.
Publicado: (2021)

Controversies in the hormonal adjuvant therapy of postmenopausal patients
por: Dowsett, M
Publicado: (2009)

The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis
por: Nie, Guangning, et al.
Publicado: (2022)

The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR(+)HER2(−) metastatic breast cancer: a retrospective study
por: Shao, Bin, et al.
Publicado: (2022)

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
por: Güth, U, et al.
Publicado: (2008)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis
por: Yu, Zhu, et al.
Publicado: (2017)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Adjuvant Hormonal Therapy in Postmenopausal Women with Breast Cancer: Physician's Choices
por: Shaikh, Asim Jamal, et al.
Publicado: (2012)

Efficacy and safety of Omega-3 polyunsaturated fatty acids in adjuvant treatments for colorectal cancer: A meta-analysis of randomized controlled trials
por: Liu, Haoshuang, et al.
Publicado: (2023)

Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients
por: Liao, Hao, et al.
Publicado: (2022)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

The role of melatonin in the development of postmenopausal osteoporosis
por: Yang, Keda, et al.
Publicado: (2022)

Tailoring Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A CYP2D6 Multiple-Genotype-Based Modeling Analysis and Validation
por: Yu, Ke-Da, et al.
Publicado: (2010)

Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study
por: Jiang, Zhouhong, et al.
Publicado: (2022)

Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis
por: Rugo, Hope S., et al.
Publicado: (2017)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2020)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Notch Signaling Pathway and Endocrine Resistance in Breast Cancer
por: Bai, Jing-Wen, et al.
Publicado: (2020)

The mechanisms of tanshinone in the treatment of tumors
por: Zhang, Pengyu, et al.
Publicado: (2023)

The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
por: Engels, C. C., et al.
Publicado: (2015)

Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry
por: Inwald, E. C., et al.
Publicado: (2015)

Re-evaluation of Adrenocorticotropic Hormone and Melanocyte Stimulating Hormone Activation of GPR139 in Vitro
por: Nepomuceno, Diane, et al.
Publicado: (2018)

Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors
por: Luo, Yanhong, et al.
Publicado: (2018)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

The potential value of exosomes as adjuvants for novel biologic local anesthetics
por: Zhang, Yunmeng, et al.
Publicado: (2023)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform
por: Eom, Kirsten Y., et al.
Publicado: (2021)

Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients
por: Yang, Fuxun, et al.
Publicado: (2020)

Interplay Between Endocrine Disruptors and Immunity: Implications for Diseases of Autoreactive Etiology
por: Popescu, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6q71p2hhhn2pafdbeqllm6nktf